Metformin (MTF) is a widely used drug for the treatment of diabetes mellitus type 2 (DM2) and frequently used as an adjuvant therapy for polycystic ovarian syndrome, metabolic syndrome, and in some cases also tuberculosis. Its protective effect on the cardiovascular system has also been described. Recently, MTF was subjected to various analyzes and studies that showed its beneficial effects in cancer treatment such as reducing cancer cell proliferation, reducing tumor growth, inducing apoptosis, reducing cancer risk in diabetic patients, or reducing likelihood of relapse. One of the MTF's mechanisms of action is the activation of adenosine-monophosphate-activated protein kinase (AMPK). Several studies have shown that AMPK/mammalian target of rapamycin (mTOR) pathway has anticancer effect in vivo and in vitro. The aim of this review is to present the anticancer activity of MTF highlighting the importance of the AMPK/mTOR pathway in the cancer process.

Department of Pharmacology and Toxicology Faculty of Pharmacy Comenius University Bratislava Slovak Republic

Zobrazit více v PubMed

ABDEL-WAHAB AF, MAHMOUD W, AL-HARIZY R. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019;150:104511. doi: 10.1016/j.phrs.2019.104511. PubMed DOI

BLOCK KI, GYLLENHAAL C, LOWE L, AMEDEI A, AMIN ARMR, AMIN A, AQUILANO K, ARBISER J, ARREOLA A, ARZUMANYAN A, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol. 2015;35:276–304. doi: 10.1016/j.semcancer.2015.09.007. PubMed DOI PMC

CANTORIA MJ, PATEL H, BOROS LG, MEUILLET EJ. Pancreatic cancer-insights into molecular mechanisms and novel approaches to early detection and treatment. London, UK: IntechOpen; 2014. Metformin and pancreatic cancer metabolism. DOI

CICCARESE F, ZULATO E, INDRACCOLO S. LKB1/AMPK Pathway and drug response in cancer: A therapeutic perspective. Oxid Med Cell Longev. 2019:8730816. doi: 10.1155/2019/8730816. PubMed DOI PMC

DELHALLE S, DUVOIX A, SCHNEKENBURGER M, MORCEAU F, DICATO M, DIEDERICH M. An introduction to the molecular mechanisms of apoptosis. Ann NY Acad Sci. 2003;1010:1–8. doi: 10.1196/annals.1299.001. PubMed DOI

DI PIETRO M, VELAZQUES C, MATZKIN ME, FRUNGIERI MB, PENA MG, ZUNIGA I, PASCUALI N, IRUSTA G, BIANCHI MS, PARBORELL F, DALHIA A. Metformin has a direct effect on ovarian cells that is dependent on organic cation transporters. Mol Cell Endocrinol. 2020;499:110591. doi: 10.1016/j.mce.2019.110591. PubMed DOI

DZUIBAK A, WOJCICKA G, WOJTAK A, BELTOWSKI J. Metabolic effect of metformin in the failing heart. Int J Mol Sci. 2018;19:2869. doi: 10.3390/ijms19102869. PubMed DOI PMC

EFFEYAN A, SABATINI DM. mTOR and cancer: Many loops in one pathway. Curr Opin Cell Biol. 2010;22:169–176. doi: 10.1016/j.ceb.2009.10.007. PubMed DOI PMC

FAN H, YU X, ZOU Z, ZHENG W, DENG X, GUO L, JIANG W, ZHAN Q, LU S-H. Metformin suppresses the esophageal carcinogenesis in rats treated with NMBzA through inhibiting AMPK/mTOR signaling pathway. Carcinogenesis. 2019;40:669–679. doi: 10.1093/carcin/bgy160. PubMed DOI

FLORY JH, HENNESSY S, BAILEY CJ, INZUCCHI SE. Reports of actic acidosis attributed to metformin, 2015–2018. Diabetes Care. 2020;43:244–246. doi: 10.2337/dc19-0923. PubMed DOI PMC

FORETZ M, GUIGAS B, BERTRAND L, POLLAK M, VIOLLET B. Metformin from mechanism of action to therapies. Cell Metab. 2014;20:953–966. doi: 10.1016/j.cmet.2014.09.018. PubMed DOI

FU P, CHEN F, PAN Q, ZHAO X, ZHAO C, CHO WC, CHEN H. The different functions and clinical significances of caveolin-1 in human adenocarcinoma and squamous cell carcinoma. Onco Targets and Therapy. 2017;10:819–835. doi: 10.2147/OTT.S123912. PubMed DOI PMC

GALDIERI L, GATLA H, VANCUROVA I, VANCURA A. Activation of AMP-activated protein kinase by metformin induces protein acetylation in prostate and ovarian cancer cells. J Biol Chem. 2016;291:25154–25166. doi: 10.1074/jbc.M116.742247. PubMed DOI PMC

GAO ZY, LIU Z, BI MH, ZHANG JJ, HAN ZQ, HAN X, WANG HY, SUN GP, LIU H. Metformin induces apoptosis via a mitochondria-mediated pathway in human breast cancer cells in vitro. Exp Ther Med. 2016;11:1700–1706. doi: 10.3892/etm.2016.3143. PubMed DOI PMC

GWINN DM, SHACKELFORD DB, EGAN DF, MIHAYLOVA MM, MERY A, VASQUEZ DS, TURK BE, SHAW RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30:214–226. doi: 10.1016/j.molcel.2008.03.003. PubMed DOI PMC

HARDIE DG, HAWLEY SA. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays. 2001;23:1112–1119. doi: 10.1002/bies.10009. PubMed DOI

HARDIE DG, ROSS FA, HAWLEY SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251–262. doi: 10.1038/nrm3311. PubMed DOI PMC

HOWELL JJ, HELLBERG K, TURNER M, TALBITT G, KOLAR MJ, ROSS DV, HOXHAJ G, SAGHATELIAN A, SHAW RJ, MANNING BD. Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab. 2017;25:463–471. doi: 10.1016/j.cmet.2016.12.009. PubMed DOI PMC

CHEN K, LI Y, GUO Z, ZENG Y, ZHANG W, WANG H. Metformin: current clinical applications in nondiabetic patients with cancer. Aging (Albany NY) 2020;12:3993–4009. doi: 10.18632/aging.102787. PubMed DOI PMC

JACKULIAK P, KUZMA M, PAYER J. Effect of antidiabetic treatment on bone. Physiol Res. 2019;68(Suppl 2):107–120. doi: 10.33549/physiolres.934297. PubMed DOI

JEON S. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016;48:e245. doi: 10.1038/emm.2016.81. PubMed DOI PMC

JIA J, BISSA B, BRECHT L, ALLERS L, CHOI SW, GU Y, ZBINDEN M, BURGE MR, TIMMINS G, HALLOWS K, BEHRENDS CH, DERETIC V. AMPK, a regulator of metabolism and autophagy, is activated by lysosomal damage via a novel galectin-directed ubiquitin signal transduction system. Mol Cell. 2020;77:1–19. doi: 10.1016/j.molcel.2019.12.028. PubMed DOI PMC

KIM WJ. Is 5′-AMP-activated protein kinase both Jekyll and Hyde in bladder cancer? Int neurourol J. 2015;19:55–66. doi: 10.5213/inj.2015.19.2.55. PubMed DOI PMC

KNUDSON CM, KORSMEYER SJ. Bcl-2 and Bax function independenty to regulate cell death. Nat Gen. 1997;16:358–363. doi: 10.1038/ng0897-358. PubMed DOI

LEE J, HONG EM, KIM JH, PARK SW, KOH DH, CHOI MH, JANG HJ, KAE SH. Metformin induces apoptosis and inhibits proliferation through the AMP-activated protein kinase and insulin-like growth facror 1 receptor pathways in the bile duct cancer cells. J Cancer. 2019;10:1734–1744. doi: 10.7150/jca.26380. PubMed DOI PMC

LYONS CL, ROCHE HM. Nutritional modulation of AMPK-impact upon metabolic-inflammation. Int J Mol Sci. 2018;19:3092. doi: 10.3390/ijms19103092. PubMed DOI PMC

MASCARAQUE M, DELGADO-WICKE P, NUEVO-TAPIOLES C, GRACIA-CAZANA T, ABARCA-LACHEN E, GONZALES S, CUEZVA JM, GILABERTE Y, JUARRANZ A. Metformin as an adjuvant to photodynamic therapy in resistant basal cell carcinoma cells. Cancers (Basel) 2020;12:668. doi: 10.3390/cancers12030668. PubMed DOI PMC

MOSCHETTA MG, LEONEL C, MASCHIO-SIGNORINI LB, BORIN TF, GELALETI GB, JARDIM-PERASSI BV, FERREIRA LC, SONEHARA NM, CARVALHO LGS, HELLMEN E, CAMPOS ZUCCARI D. Evaluation of angiogenesis process after metformin and LY294002 treatment in mammary tumor. Anticancer Agents Med Chem. 2019;19:655–666. doi: 10.2174/1871520619666181218164050. PubMed DOI

PODHORECKA M, IBANEZ B, DMOSZYNSKA A. Metformin - its potential anti-cancer and anti-aging effects. Postepy Hig Med Dosw. 2017;71:170–175. doi: 10.5604/01.3001.0010.3801. PubMed DOI

RENA G, HARDIE DG, PEARSON E. The mechanisms of action of metformin. Diabetologia. 2017;60:1577–1585. doi: 10.1007/s00125-017-4342-z. PubMed DOI PMC

SANLI T, STEINBERG GR, SINGH G, TSAKIRIDIS T. AMP-activated protein kinase (AMPK) beyond metabolism a novel genomic stress sensor participating in the DNA damage response pathway. Cancer Biol Ther. 2014;15:156–169. doi: 10.4161/cbt.26726. PubMed DOI PMC

SAXTON RA, SABATINI DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–976. doi: 10.1016/j.cell.2017.02.004. PubMed DOI PMC

SARAEI P, ASADI I, KAKAR MA, MORADI-KOR N. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag Res. 2019;11:3295–3313. doi: 10.2147/CMAR.S200059. PubMed DOI PMC

SCHNEIDER MB, MATSUZAKI H, HAORAH J, ULRICH A, STANDOP J, DING XZ, ADRIAN TE, POUR PM. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterol. 2001;120:1263–1270. doi: 10.1053/gast.2001.23258. PubMed DOI

STAGE TB, BROSEN K, CHRISTENSEN MM. A comprehensive review of drug-drug interactions with metformin. Clin Pharmacokinet. 2015;54:811–824. doi: 10.1007/s40262-015-0270-6. PubMed DOI

TADAKAWA M, TAKEDA T, LI B, TSUIJI K, YAEGASHI N. The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1/hypoxia-inducible factor-1α signaling path-way in ELT-3 cells. Mol Cell Endocrinol. 2015;399:1–8. doi: 10.1016/j.mce.2014.08.012. PubMed DOI

TONINI T, ROSSI F, CLAUDIO P. Molecular basis of angiogenesis and cancer. Oncogene. 2003;22:6549–6556. doi: 10.1038/sj.onc.1206816. PubMed DOI

VACANTE F, SENESI P, MONTESANO A, PAINI S, LUZI L, TERRUZZI I. Metformin counteracts HCC progression and metastasis enhancing KLF6/p21 expression and downregulating the IGF axis. Int J Endocrinol. 2019;2019:7570146. doi: 10.1155/2019/7570146. PubMed DOI PMC

VARA-CIRUELOS D, DANDAPANI M, RUSSELL FM, GRZES KM, ATRIH A, FORETZ M, VIOLLET B, LAMONT DJ, CANTRELL DA, HARDIE DG. Phenformin, But Not Metformin, Delays Development of T Cell Acute Lymphoblastic Leukemia/Lymphoma via Cell-Autonomous AMPK Activation. Cell Rep. 2019;27:690–698. doi: 10.1016/j.celrep.2019.03.067. PubMed DOI PMC

VOGELSTEIN B, PAPADOUPOULOS N, VELCULESCU VE, SHOU S, DIAZ LA, Jr, KINZLER KW. Cancer genome landscapes. Science. 2013;339:1546–1558. doi: 10.1126/science.1235122. PubMed DOI PMC

WHITBURN J, EDWARDS CM, SOORIAKUMARAN P. Metformin and prostate cancer: a new role for an old drug. Curr Urol Rep. 2017;18:46. doi: 10.1007/s11934-017-0693-8. PubMed DOI PMC

XIONG ZS, GING SF, SI W, JIANG T, LI QL, WANG TJ, WU RY, JIANG K. Effect of metformin on cell proliferation, apoptosis, migration and invasion in A172 glioma cells and its mechanisms. Mol Med Rep. 2019;20:887–894. doi: 10.3892/mmr.2019.10369. PubMed DOI PMC

YAMASHITA T, KATO K, FUJIHARA S, IWAMA H, MORISHITA A, YAMANA H, KOBAYASHI K, KAMADA H, CHIYO T, KOBARA H, TSUTSUI K, OKANO K, SUZUI Y, MASAKI T. Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest. Anti-cancer drugs. 2020;31:231–240. doi: 10.1097/CAD.0000000000000870. PubMed DOI

YANG L, MA B, SUN G, DONG CH, MA B. Antiproliferative and antiangiogenic effects of metformin on multidrug-resistant MCF-7 cells. Int J Clin Exp Med. 2018;11:6776–6783.

ZAIDI S, GANDHI J, JOSHI G, SMITH NL, KHAN SA. The anticancer potential of metformin on prostate cancer. Prostate Cancer Prostatic Dis. 2019;22:351–361. doi: 10.1038/s41391-018-0085-2. PubMed DOI

ZHANG K, WANG J, WANG J, LUH F, LIU X, YANG L, LIU Y-R, SU L, YANG Y-CHSH, CHU P, YEN Y. LKB1 deficiency promotes proliferation and invasion of glioblastoma trough activation of mTOR and focal adhesion kinase signaling pathways. Am J Cancer Res. 2019;9:1650–1663. PubMed PMC

ZHAO J, MA Y, ZHANG Y, FU B, WU X, LI Q, CAI G, CHEN X, BAY X-Y. Low-dose 2-deoxyglucose and metformin synergically inhibit proliferation of human polycystic kidney cells by modulating glucose metabolism. Cell Death Discov. 2019;5:76. doi: 10.1038/s41420-019-0156-8. PubMed DOI PMC

ZI F, ZI H, LI Y, HE J, SHI Q, CAI Z. Metformin and cancer: An existing drug for cancer prevention and therapy (Review) Oncol Lett. 2018;15:683–690. doi: 10.3892/ol.2017.7412. PubMed DOI PMC

ZONCU R, EFEYAN A, SABATINI DM. mTOR: form growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21–35. doi: 10.1038/nrm3025. PubMed DOI PMC

Caffeic Acid and Diseases-Mechanisms of Action

PTEN mutations as predictive marker for the high-grade endometrial cancer development in slovak women